Integral Diagnostics Ltd
IDX · ASX · Australia
Price data from its IDX listing on CXA
integraldiagnostics.com.auFinancials as of FY2025–FY2026
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleLevered free cash flow is $36.69M, above the global median of $18.58M
- PositionCurrent ratio is 0.67×, lower than 95% of its Diagnostics & Research peers (median 2.44×)
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
6.63%Above 5Y avg (2.49%)
Annual Rate
AUD 0.12Paid semi-annual
Payout Ratio
125.9%High
Last Ex-Dividend
Aug 28, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2026, balance sheet FY2025, cash-flow statement FY2026. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
777.29MAUD532.69M · vs all stocks (USD)
Trailing P/E
34.67xvs Diagnostics & Research peers
Revenue (TTM)
788.62MAUD540.46M · vs all stocks (USD)
Profit Margin
2.78%vs Diagnostics & Research peers
Beta
0.1820xvs all stocks
52-Week Change
-27.02%vs all stocks
Forward Annual Dividend Yield
6.63%vs all stocks
Market Capitalization
777.29MAUD532.69M · vs all stocks (USD)
Enterprise Value
1.34BAUD921.57M · vs all stocks (USD)
Trailing P/E
34.67xvs Diagnostics & Research peers
Forward P/E
13.39xvs Diagnostics & Research peers
Price to Sales (TTM)
0.9856xvs Diagnostics & Research peers
Price to Book (MRQ)
1.15xvs Diagnostics & Research peers
Enterprise to Revenue
1.71xvs Diagnostics & Research peers
Enterprise to EBITDA
11.96xvs Diagnostics & Research peers
Profit Margin
2.78%vs Diagnostics & Research peers
Operating Margin
10.26%vs Diagnostics & Research peers
Return on Assets (TTM)
3.24%vs Diagnostics & Research peers
Return on Equity (TTM)
3.21%vs Diagnostics & Research peers
Revenue (TTM)
788.62MAUD540.46M · vs all stocks (USD)
Revenue per Share (TTM)
2.12AUDUpdated Oct 29, 2026Quarterly Revenue Growth
5.60%vs Diagnostics & Research peers
Gross Profit (TTM)
243.36MAUD166.78M · vs all stocks (USD)
EBITDA (TTM)
126.59MAUD86.75M · vs all stocks (USD)
Net Income (TTM)
21.93MAUD15.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
320.60%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
95.24MAUD65.27M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
53.54MAUD36.69M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1200AUDUpdated Oct 29, 2026Forward Annual Dividend Yield
6.63%vs all stocks
Trailing Annual Dividend Rate
0.0930AUDUpdated Oct 29, 2026Trailing Annual Dividend Yield
5.14%vs all stocks
5-Year Average Dividend Yield
2.49%vs all stocks
Payout Ratio
125.86%vs Diagnostics & Research peers
Minority Interest (Equity)
942.00KAUDFY2025 · Jun 30, 2025Revenue
788.62MAUDFY2026 · Jun 30, 2026Cost of Goods Sold
35.94MAUDFY2026 · Jun 30, 2026Gross Profit
752.67MAUDFY2026 · Jun 30, 2026Operating Income
68.44MAUD46.91M · vs all stocks (USD)
Pre-tax Income
32.11MAUDFY2026 · Jun 30, 2026Income Tax Expense
10.07MAUDFY2026 · Jun 30, 2026Net Income
22.04MAUDFY2026 · Jun 30, 2026EBIT
52.47MAUDFY2026 · Jun 30, 2026EBITDA (Income Statement)
126.59MAUDFY2026 · Jun 30, 2026Selling, General & Administrative
527.61MAUDFY2026 · Jun 30, 2026Other Operating Expenses
82.51MAUDFY2026 · Jun 30, 2026Non-operating Interest Income
1.26MAUDFY2026 · Jun 30, 2026Non-operating Interest Expense
20.37MAUDFY2026 · Jun 30, 2026EPS (Basic)
0.0590AUDFY2026 · Jun 30, 2026EPS (Diluted)
0.0580AUDFY2026 · Jun 30, 2026Basic Shares Outstanding
372.85MSharesFY2026 · Jun 30, 2026Diluted Shares Outstanding
372.85MSharesFY2026 · Jun 30, 2026Minority Interests (P&L)
-107.00KAUDFY2026 · Jun 30, 2026Cash & Cash Equivalents (End of Period)
51.29MAUDFY2026 · Jun 30, 2026Income Tax Paid
13.69MAUDFY2026 · Jun 30, 2026Interest Paid
28.77MAUDFY2026 · Jun 30, 2026Long-term Debt Issuance
10.00MAUDFY2026 · Jun 30, 2026Long-term Debt Payments
-10.00MAUDFY2026 · Jun 30, 2026Common Dividends Paid
-25.93MAUDFY2026 · Jun 30, 2026Other Financing Charges
-19.55MAUDFY2026 · Jun 30, 2026Net Financing Cash Flow
-45.48MAUDFY2026 · Jun 30, 2026Shares Outstanding
372.49MSharesUpdated Oct 29, 2026Float Shares
339.29MSharesUpdated Oct 29, 2026% Held by Insiders
4.88%vs all stocks
% Held by Institutions
49.22%vs all stocks
Total Cash (MRQ)
51.29MAUD35.15M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1380AUDUpdated Oct 29, 2026Total Debt (MRQ)
597.10MAUD409.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.8762xvs Diagnostics & Research peers
Current Ratio (MRQ)
0.6690xvs Diagnostics & Research peers
Book Value per Share (MRQ)
1.81AUDUpdated Oct 29, 2026Total Assets
1.43BAUD977.59M · vs all stocks (USD)
Total Current Assets
95.28MAUDFY2025 · Jun 30, 2025Total Liabilities
732.53MAUDFY2025 · Jun 30, 2025Total Non-current Assets
1.33BAUDFY2025 · Jun 30, 2025Total Non-current Liabilities
591.87MAUDFY2025 · Jun 30, 2025Total Current Liabilities
140.66MAUDFY2025 · Jun 30, 2025Cash
52.10MAUDFY2025 · Jun 30, 2025Cash & Cash Equivalents
52.10MAUDFY2025 · Jun 30, 2025Accounts Receivable
30.08MAUDFY2025 · Jun 30, 2025Inventory
2.52MAUDFY2025 · Jun 30, 2025Accounts Payable
20.59MAUDFY2025 · Jun 30, 2025Short-term Debt
20.32MAUDFY2025 · Jun 30, 2025Deferred Revenue
2.67MAUDFY2025 · Jun 30, 2025Other Current Liabilities
8.45MAUDFY2025 · Jun 30, 2025Long-term Debt
564.68MAUDFY2025 · Jun 30, 2025Other Non-current Liabilities
486.00KAUDFY2025 · Jun 30, 2025Common Stock (Book)
735.40MAUDFY2025 · Jun 30, 2025Retained Earnings
-37.13MAUDFY2025 · Jun 30, 2025Total Shareholders' Equity
693.94MAUD475.57M · vs all stocks (USD)
52-Week Low
1.77AUDUpdated Oct 29, 202652-Week High
2.71AUDUpdated Oct 29, 202652-Week Change
-27.02%vs all stocks
Beta
0.1820xvs all stocks
50-Day MA
2.22AUDUpdated Oct 29, 2026200-Day MA
2.24AUDUpdated Oct 29, 2026Avg 10-Day Volume
1.08MSharesUpdated Oct 29, 2026Avg 30-Day Volume
893.87KSharesUpdated Oct 29, 2026Diluted EPS (TTM)
0.0600AUDUpdated Oct 29, 2026Other Income / Expense
-3.99MAUDFY2026 · Jun 30, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.67×, lower than 95% of its Diagnostics & Research peers (median 2.44×)Significant
Current ratio: 0.67Industry median: 2.44Industry P5: 0.70Peers compared: 29.00
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.26Dividend per Share: 0.09Earnings per Share: 0.06
Financial Health
Altman Z-Score 1.07: distress zoneCritical
Altman Z-Score: 1.07
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Levered free cash flow is $36.69M, above the global median of $18.58MNotable
Levered free cash flow (USD): 36,689,121.561Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Advanced Power Electronics Corp.
Tier 1ProductionThroughput-Bound ConversionFlowRisk
Dingli Corp Ltd.
Tier 1ProductionThroughput-Bound ConversionFlow
Vibhavadi Medical Center Public Company Limited
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Guangdong Sanhe Pile Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Hyliion Holdings Corp.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Zhejiang Mustang Battery Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Taiwan Sakura Corp.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Canature Health Technology Inc.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Changzhou Shichuang Energy Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Ningbo Shenglong Automotive Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule